<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680050</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics16121554</article-id><article-id pub-id-type="publisher-id">pharmaceutics-16-01554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>miR-195-5p Inhibits Colon Cancer Progression via KRT23 Regulation</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7988-1917</contrib-id><name><surname>Piccinno</surname><given-names>Emanuele</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0273-2825</contrib-id><name><surname>Scalavino</surname><given-names>Viviana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><name><surname>Labarile</surname><given-names>Nicoletta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1661-5504</contrib-id><name><surname>Armentano</surname><given-names>Raffaele</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5140-8060</contrib-id><name><surname>Giannelli</surname><given-names>Gianluigi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2971-0802</contrib-id><name><surname>Serino</surname><given-names>Grazia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-pharmaceutics-16-01554" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Salazar</surname><given-names>Luis A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-16-01554">National Institute of Gastroenterology S. De Bellis, IRCCS Research Hospital, Via Turi 27, 70013 Castellana Grotte, BA, Italy; <email>emanuele.piccinno@irccsdebellis.it</email> (E.P.); <email>viviana.scalavino@irccsdebellis.it</email> (V.S.); <email>nicoletta.labarile@irccsdebellis.it</email> (N.L.); <email>raffaele.armentano@irccsdebellis.it</email> (R.A.); <email>gianluigi.giannelli@irccsdebellis.it</email> (G.G.)</aff><author-notes><corresp id="c1-pharmaceutics-16-01554"><label>*</label>Correspondence: <email>grazia.serino@irccsdebellis.it</email></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1554</elocation-id><history><date date-type="received"><day>18</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>02</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: KRT23 was recently discovered as an epithelial-specific intermediate filament protein in the type I keratin family. Many studies have underlined keratin&#x02019;s involvement in several biological processes as well as in the pathogenesis of different diseases. Specifically, KRT23 was reported to affect the structural integrity of epithelial cells and to trigger cellular signaling leading to the onset of cancer. The aim of this study is to characterize a novel mechanism based on miR-195-5p/KRT23 in colorectal cancer. Methods: KRT23 mRNA and protein expression were characterized in FFPE sections from patients with CRC. The effects of miR-195-5p on KRT23 expression at the mRNA and protein levels were assessed by transient transfection experiments with mimic and inhibitor molecules. Cell attachment/detachment, migration, invasion, clone formation, and apoptosis were evaluated in human CRC cell lines after miR-195-5p mimic transfection. Results: We identified KRT23 as a putative target of miR-195-5p, a microRNA that we previously demonstrated to be reduced in CRC. We have proved the KRT23 expression deregulation in the tumoral section compared to adjacent normal mucosa in patients with CRC, according to the data derived from the public repository. We proved that the gain of miR-195-5p decreased the KRT23 expression. Conversely, we demonstrated that the inhibition of miR-195-5p led to an increase in KRT23 expression levels. We have demonstrated the in vitro effectiveness of miR-195-5p on CRC progression and that the in vivo intraperitoneal delivery of miR-195-5p mimic lowered colonic KRT23 mRNA and protein expression. Conclusions: These findings highlight a new regulatory mechanism by miR-195-5p in CRC affecting the keratin intermediate filaments and underline the miR-195-5p potential clinical properties.</p></abstract><kwd-group><kwd>miR-195-5p</kwd><kwd>keratin 23</kwd><kwd>cytokeratins</kwd><kwd>colorectal cancer</kwd></kwd-group><funding-group><award-group><funding-source>Italian Ministry of Health</funding-source><award-id>Ricerca Corrente 2024</award-id></award-group><funding-statement>This work was supported by a grant from the Italian Ministry of Health [Ricerca Corrente 2024].</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-16-01554"><title>1. Introduction</title><p>The three-dimensional organization of animal tissues is provided by the cytoskeleton, a dynamic system of interlinking protein filaments embedded within the cytoplasm of eukaryotic cells connecting to the neighboring cells, determining the cell shape and coordinating cellular movement [<xref rid="B1-pharmaceutics-16-01554" ref-type="bibr">1</xref>]. The cytoskeleton&#x02019;s ability to integrate the cells within the external environment and to transport cargoes within the cells is closely linked to several biological processes. To achieve these functions, the component polymers and regulatory proteins of the cytoskeleton are in constant flux and coordinate a multitude of cytoplasmic activities [<xref rid="B2-pharmaceutics-16-01554" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-16-01554" ref-type="bibr">3</xref>].</p><p>The three major protein families that form the filamentous structures of the cytoskeleton are microfilaments composed of several actin isoforms, microtubules consisting of &#x003b1;- and &#x003b2;-tubulin, and the intermediate filaments associated with molecular motors and regulatory protein complexes [<xref rid="B4-pharmaceutics-16-01554" ref-type="bibr">4</xref>].</p><p>The keratins are the most abundant and typical intermediate filaments of epithelial cells subjected to continuous turnovers due to the exposition of epithelia to multiple forms of stress. As a result of the renewal and repair of the epithelia, the cytoskeleton organization is dynamically remodeled to ensure the cycle of proliferation, migration, and differentiation and the characteristic functions of epithelial cells [<xref rid="B5-pharmaceutics-16-01554" ref-type="bibr">5</xref>].</p><p>Keratins include a large group of acidic and basic-to-neutral isotypes divided into 28 type I and 26 type II, respectively, that, beyond determining the cell mechanics and cohesion, act as targets and effectors of chemical signals interacting with major signaling pathways in an isoform-specific manner [<xref rid="B6-pharmaceutics-16-01554" ref-type="bibr">6</xref>]. In this way, the specific keratin expression and structure affect cell adhesion, migration, and growth [<xref rid="B7-pharmaceutics-16-01554" ref-type="bibr">7</xref>]. An alteration in keratin expression leads to pathological conditions such as colorectal cancer (CRC) [<xref rid="B8-pharmaceutics-16-01554" ref-type="bibr">8</xref>].</p><p>Keratin 23 (KRT23) is an acidic type I keratin that was first identified in pancreatic cancer and subsequently was detected as a tumor-specific antigen in hepatocellular carcinoma (HCC) patients [<xref rid="B9-pharmaceutics-16-01554" ref-type="bibr">9</xref>]. Since then, increasing evidence has shown the pro-cancer properties of KRT23 in certain tumors, although its role has not been comprehensively studied. The KRT23 amplification mediated by MYC promoted cell proliferation, inducing liver carcinogenesis [<xref rid="B9-pharmaceutics-16-01554" ref-type="bibr">9</xref>]. In ovarian cancer, the KRT23 overexpression promoted cell migration and epithelial&#x02013;mesenchymal transition (EMT) progression by regulating the TGF-&#x003b2;)/Smad pathway [<xref rid="B10-pharmaceutics-16-01554" ref-type="bibr">10</xref>]. In addition, in colon cancer cells the upregulation of KRT23 affects the expression of crucial mediators that were involved in apoptosis and the cell cycle [<xref rid="B11-pharmaceutics-16-01554" ref-type="bibr">11</xref>].</p><p>MicroRNA (miRNAs) are a family of small, single-stranded, non-coding RNA molecules that have a critical function in gene expression regulation at post-transcriptional levels. Physiologically, they bind to complementary mRNA sequences, affecting several biological processes through feedback mechanisms [<xref rid="B12-pharmaceutics-16-01554" ref-type="bibr">12</xref>]. Since miRNAs are involved in development, differentiation, proliferation, apoptosis, and metabolic activity, any dysregulation of their expression could lead to the onset of many diseases [<xref rid="B13-pharmaceutics-16-01554" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-16-01554" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-16-01554" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-16-01554" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-16-01554" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-16-01554" ref-type="bibr">18</xref>]. Recently, several works have established the involvement of miRNAs in targeting specific genes that affect the intestinal barrier structure and function, triggering inflammatory response [<xref rid="B15-pharmaceutics-16-01554" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-16-01554" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-16-01554" ref-type="bibr">17</xref>]. Similarly, we demonstrated the miR-195-5p impact in reversing the aberrant expression of PNN, a desmosome-associated protein involved in CRC development. Moreover, several miRNAs that are implicated in tumorigenesis altering the expression of keratin proteins have been identified.</p><p>miR-133a, miR-199a*, and miR-30-3p play a key role as tumor suppressors in bladder cancer, acting through a mechanism that underlines the transcriptional repression of KRT7 [<xref rid="B19-pharmaceutics-16-01554" ref-type="bibr">19</xref>]. Downregulation of KRT16 by miR-365-3p increased the degradation of &#x000df;5-integrin and c-Met via a lysosomal cascade that led to the downstream repression of the Src/STAT3/FAK/ERK pathway and enhanced the chemosensitivity of oral squamous carcinoma cell lines towards 5-fluorouracil (5-FU) [<xref rid="B20-pharmaceutics-16-01554" ref-type="bibr">20</xref>].</p><p>Considering the pathophysiological relevance of intermediate filament proteins of epithelial cells in tumorigenesis, the biological characterization of miRNAs abilities in the regulation of keratin could gain new knowledge in CRC pathogenesis and treatment.</p><p>In this work, we aimed to evaluate the involvement of KRT23 in colorectal cancer, focusing on its molecular regulation. We firstly demonstrated the KRT23 deregulation in patients with CRC. Then, we highlighted that miR-195-5p regulated the expression of KRT23 and functionally characterized the role of miR-195-5p in the CRC progression. These findings enhance the potential use of this miRNA in CRC treatment.</p></sec><sec id="sec2-pharmaceutics-16-01554"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-16-01554"><title>2.1. CRC Patients Tissues</title><p>Sixty formalin-fixed and paraffin-embedded (FFPE) human tissues with tumor and adjacent normal sections were obtained from 30 patients affected by CRC that were enrolled retrospectively in our institute in accordance with the following criteria: No one was subjected to therapy prior to the surgical resection, and thus patients with lower rectum cancer, who were undergoing therapy/treatment, were selectively excluded. Additionally, patients were selected without mutations. The research was performed following the principles of the Declaration of Helsinki. The study was approved by the local institutional ethics review board (Istituto Tumori Giovanni Paolo II, Bari, Italy n&#x000b0; 379/2020 of 16 September 2020). All participants signed a written informed consent. Tissue sections were used for hematoxylin and eosin staining and analyzed by a clinician to assess the propriety of the tissues and their phenotypical and/or pathological profiling.</p></sec><sec id="sec2dot2-pharmaceutics-16-01554"><title>2.2. RNA Isolation and RT-PCR of Human Sections</title><p>Tissues were incubated with a Deparaffinization Solution (Qiagen, Hilden, Germany). For total RNA isolation, we used the miRNeasy FFPE kit (Qiagen, Hilden, Germany) accordingly to the producer&#x02019;s indications.</p><p>For KRT23 evaluation, retrotranscription was performed using SuperScript&#x02122; VILO&#x02122; MasterMix (Thermo Fisher Scientific, Bremen, Germany), and the RT-PCR amplification reactions were assessed on a CFX96 System (Biorad Laboratories, Hercules, CA, USA) with the SsoAdvanced Universal SYBR Green Supermix (BioRad Laboratories, Hercules, CA, USA) and the QuantiTect Primer Assay for GAPDH and KRT23 (Qiagen, Hilden, Germany). GAPDH gene was used as a reference standard to normalize the KRT23 expression. The 2<sup>&#x02212;&#x00394;Ct</sup> formula was used to calculate the KRT23 relative expression.</p></sec><sec id="sec2dot3-pharmaceutics-16-01554"><title>2.3. Immunohistochemistry (IHC)</title><p>Prior to immunostaining, FFPE tissues were cut into three &#x003bc;m sections and mounted on Apex Bond IHC slides (Leica Biosystems, Buffalo Grove, IL, USA). The specimens were deparaffinized and the immunohistochemical staining was carried out in the BOND III automated immunostainer (Leica Biosystems, Buffalo Grove, IL, USA) using the anti-KRT23 primary antibody (ab156569, Abcam, Cambridge, UK; 1:100 dilution). Sections were then counterstained with hematoxylin. For antigen retrieval, the BOND Epitope Retrieval Solution 2 (Leica Biosystems, Buffalo Grove, IL, USA) with citrate buffer pH 6 was used. The Bond Polymer Refine Detection Kit (Leica Biosystems, Buffalo Grove, IL, USA) was employed as a chromogen reagent. IHC scoring was performed by a pathologist on the basis of extensiveness and intensity of biomarker as follows: 0, (no staining) negative; 1, weak expression; 2, moderate expression; and 3, strong expression.</p></sec><sec id="sec2dot4-pharmaceutics-16-01554"><title>2.4. Cell Culture</title><p>HCT116 and HT29 colonic epithelial cell lines were acquired from ATCC (American Type Culture Collection, Manassas, VA, USA) and grown in Dulbecco&#x02019;s Modified Eagle Medium (DMEM, Thermo Fisher Scientific, Waltham, MA, USA) using 10% heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA), 1% streptomycin/penicillin (Thermo Fisher Scientific, Waltham, MA, USA), 10 mM HEPES (Sigma-Aldrich, St. Louis, MO, USA), and 1 mM sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA) as supplements.</p><p>For RNA and protein extraction, cells were seeded in 12-well and 6-well plates, respectively. HT29 and HCT116 were transfected with molecules of miR-195-5p mimic or inhibitor (Life Technologies, Carlsbad, CA, USA) at concentrations of 30 nM and 50 nM using TKO transfection reagent (Mirus Bio LLC, Madison, WI, USA) once they reached the confluence. For attachment/detachment and clone formation assay, cells were plated in 6-wells before transfection.</p></sec><sec id="sec2dot5-pharmaceutics-16-01554"><title>2.5. RNA Extraction and RT-PCR of CRC Cell Lines</title><p>Mice tissues and cell cultures were lysed with TRIzol reagent (Invitrogen by Thermo Fisher Scientific, Waltham, MA, USA) to extract total RNA following the producer&#x02019;s recommendations. The NanoDrop ND-2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) was used to establish the concentrations of RNA samples.</p><p>For KRT23 quantification, the iScript Reverse Transcription Supermix (BioRad Laboratories, CA, USA) was used for reverse transcription according to the provider&#x02019;s protocol. Real-time PCR amplification reactions were assessed in 20 &#x003bc;L of final volume on a CFX96 System (Biorad Laboratories, Hercules, CA, USA) using the SsoAd-vanced Universal SYBR Green Supermix (BioRad Laboratories, Hercules, CA, USA) and the QuantiTect Primer Assay for <italic toggle="yes">KRT23</italic> (Biorad Laboratories, Hercules, CA, USA) and <italic toggle="yes">GAPDH</italic> (Qiagen, Hilden, Germany).</p><p>The KRT23 and GAPDH expressions were carried out in four independent experiments. GAPDH gene amplification was used as a reference standard to normalize the relative expression of KRT23. The 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> formula was used to calculate the KRT23 relative expression.</p></sec><sec id="sec2dot6-pharmaceutics-16-01554"><title>2.6. Western Blot</title><p>Total protein from HCT116 and HT29 cell lines was obtained by means of T-PER Tissue Protein Extraction Reagent (Thermo Fisher Scientific, Waltham, MA, USA) with cocktail proteinase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). The Bradford colorimetric assay (BioRad Laboratories, Hercules, CA, USA) was used to determine the protein concentration. For each sample, an equal amount of proteins was heat-denatured at 100 &#x000b0;C for 5 min in reducing Laemmli Sample Buffer (Biorad Laboratories, Hercules, CA, USA). Proteins were electroformed on 4&#x02013;20% Mini-PROTEAN TGX Stain-Free Gels (Biorad Laboratories, Hercules, CA, USA) and transferred onto PVDF membranes (0.2 &#x003bc;m pore size) (Biorad Laboratories, Hercules, CA, USA). The primary and secondary antibodies were incubated in an automated iBind Flex Western Device (Thermo Fisher Scientific, Waltham, MA, USA), and the signal intensities were revealed using the Chemidoc System (Biorad Laboratories, Hercules, CA, USA). Blots were analyzed with Image Lab Software version 5.2.1 (Biorad Laboratories, Hercules, CA, USA) and quantified by ImageJ Software 1.54d. &#x003b2;-Tubulin expression was used to normalize the target protein signal.</p><p>Primary antibody of rabbit monoclonal anti-KRT23 (ab156569, Abcam, Cambridge, UK; 1:2000 dilution) and mouse monoclonal &#x000df;-Tubulin (sc-166729, Santa Cruz Biotechnology, Inc., Heidelberg, Germany; dilution 1:1000) as well as secondary antibodies of Goat Anti-mouse IgG-(H + L)-HRP conjugate (170-6516, Biorad Laboratories, CA, USA; dilution 1:500) and Goat Anti-rabbit IgG-(H + L)-HRP conjugate (#31466, Invitrogen, Carlsbad, CA, USA; dilution 1:2500) were used for western blot analysis.</p></sec><sec id="sec2dot7-pharmaceutics-16-01554"><title>2.7. Attachment and Detachment Assay</title><p>Forty-eight hours post-transfection, cells were harvested, counted, and replated in 24-well plates (5 &#x000d7; 10<sup>4</sup>/well) (Corning, Corning, NY, USA). For attachment assay, after 1 h of incubation at 37 &#x000b0;C, unattached cells were washed away. After trypsinization, the attached cell number was determined using trypan blue stain by means of the Countess&#x02122; 3 Automated Cell Counter (Thermo Fisher Scientific, Waltham, MA, USA).</p><p>For cell detachment assays, transfected cells (1 &#x000d7; 10<sup>5</sup>/well) were cultured in 24-well plates for 24 h and detached using 0.05% trypsin for 1 or 2 min. Then, the detached cells were collected and automatically counted while the remaining cells were re-incubated with 0.25% trypsin to detach and automatically counted. The data were presented as a percentage of the detached cells to total cells.</p></sec><sec id="sec2dot8-pharmaceutics-16-01554"><title>2.8. Clone Formation Assay</title><p>HCT116 and HT29 transfected cells were trypsinized and plated in 6-well plates (5 &#x000d7; 10<sup>2</sup> cells/well). The cells were kept for two weeks at 37 &#x000b0;C with 5% CO<sub>2</sub> in a humidified incubator to form colonies. The colonies formed were PBS washed, fixed with 4% paraformaldehyde for 15 min, and stained with crystal violet. After washing, images of the stained plates were captured, and the cell colonies that contained more than 50 cells were counted using ImageJ Software 1.54d. Each treatment was performed in triplicate.</p></sec><sec id="sec2dot9-pharmaceutics-16-01554"><title>2.9. Annexin V Staining</title><p>After transfection, HCT116 and HT29 cell lines were counted, stained with Muse Annexin V and Dead Cell Reagent (Cytek Biosciences, Fremont, CA, USA), and incubated at room temperature for 20 min in the dark. Apoptosis detection was performed with the Guava Muse Cell Analyzer (Luminex Corp, Austin, TX, USA) according to the provider&#x02019;s directive.</p></sec><sec id="sec2dot10-pharmaceutics-16-01554"><title>2.10. Immunofluorescence in FFPE from Mice Tissue</title><p>Three &#x003bc;m sections of FFPE colon parts from mice were deparaffinized, and antigen retrieval was performed using citrate buffer pH 6 in a water bath at 98 &#x000b0;C for 30 min. Tissue slides were treated with a solution of 0.5% Triton X-100 in PBS 1&#x000d7; for 10 min at room temperature and then blocked in PBS + BSA 5% for 1 h at room temperature. Then, slides were incubated with primary antibody mouse cytokeratin 23 (sc-365892, Santa Cruz Biotechnologies, Inc., Heidelberg, Germany; dilution 1:100) overnight at 4 &#x000b0;C and then with secondary antibody chicken anti-mouse IgG (H + L) Alexa Fluor 488 (A-21200, Invitrogen, dilution 1:200) for 1 h. Slides were mounted with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) and a glass coverslip. Images were acquired with a fluorescence microscope (Eclipse Ti2, Nikon Inc., Melville, NY, USA) using filters for DAPI and FITC using a 20&#x000d7; objective lens.</p></sec><sec id="sec2dot11-pharmaceutics-16-01554"><title>2.11. Bioinformatic and Statistical Analysis</title><p>The GEPIA tool (<uri xlink:href="http://gepia.cancer-pku.cn/index.html">http://gepia.cancer-pku.cn/index.html</uri>, accessed on 31 July 2023 [<xref rid="B21-pharmaceutics-16-01554" ref-type="bibr">21</xref>]) was exploited to evaluate KRT23 expression in tumoral and normal tissue.</p><p>miR-195-5p gene targets were predicted with the miRwalk algorithm (<uri xlink:href="http://bioinfo.univ-rouen.fr/mirabel/">http://bioinfo.univ-rouen.fr/mirabel/</uri>; accessed on 25 September 2023 [<xref rid="B22-pharmaceutics-16-01554" ref-type="bibr">22</xref>]). Data were analyzed using GraphPad Prism software version 9.0.0 and are shown as mean&#x02009; &#x000b1; &#x02009;SEM. Statistical significance of data obtained from at least three independent experiments was analyzed with a two-tailed Student&#x02019;s <italic toggle="yes">t</italic>-test. The difference between experimental conditions was statistically significant at <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-16-01554"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-16-01554"><title>3.1. KRT23 as a Target of miR-195-5p</title><p>In our recent works, we investigated the miR-195-5p involvement in CRC [<xref rid="B14-pharmaceutics-16-01554" ref-type="bibr">14</xref>,<xref rid="B23-pharmaceutics-16-01554" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-16-01554" ref-type="bibr">24</xref>]. To further assess the molecular mechanism regulated by miR-195-5p in the CRC development, we conducted a bioinformatic analysis to predict its potential target genes, focusing our attention also on the 5&#x02019; untranslated region (UTR) and the coding sequence (CDS) regulatory regions. The bioinformatic analysis highlighted that miR-195-5p has two putative binding sites located in the CDS region of the <italic toggle="yes">KRT23</italic> gene (<xref rid="pharmaceutics-16-01554-f001" ref-type="fig">Figure 1</xref>). This gene is essential to guaranteeing tissue homeostasis, and its aberrant expression may lead to the onset of CRC.</p></sec><sec id="sec3dot2-pharmaceutics-16-01554"><title>3.2. KRT23 Expression in Patients with CRC</title><p>In order to evaluate the <italic toggle="yes">KRT23</italic> expression in patients with CRC, we used the TCGA and GTEx databases containing public cancer sequencing data. The analysis performed by the GEPIA tool underlined that CRC tissue has more expression of <italic toggle="yes">KRT23</italic> gene expression than adjacent tissue (<italic toggle="yes">p</italic> &#x0003c; 0.01; <xref rid="pharmaceutics-16-01554-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B21-pharmaceutics-16-01554" ref-type="bibr">21</xref>].</p><p>To further investigate the deregulation of <italic toggle="yes">KRT23</italic> in CRC, we analyzed the KRT23 expression levels in our cohort of 30 patients with CRC. For each patient we compared the tumor expression value with those of the corresponding adjacent normal sections. Demographic and clinical characteristics of patients are summarized in <xref rid="pharmaceutics-16-01554-t001" ref-type="table">Table 1</xref>.</p><p>Data from real-time PCR confirmed the aberrant overexpression of <italic toggle="yes">KRT23</italic> in tumoral sections when compared to adjacent normal tissues (<italic toggle="yes">p</italic> &#x0003c; 0.001; <xref rid="pharmaceutics-16-01554-f003" ref-type="fig">Figure 3</xref>A). In addition, we demonstrated a negative correlation between <italic toggle="yes">KTR23</italic> and miR-195-5p expression previously analyzed on the same samples [<xref rid="B22-pharmaceutics-16-01554" ref-type="bibr">22</xref>] (r = &#x02212;0.249, <italic toggle="yes">p</italic> &#x0003c; 0.05; <xref rid="pharmaceutics-16-01554-f003" ref-type="fig">Figure 3</xref>B). This negative correlation indicates that miR-195-5p may regulate KRT23.</p><p>To clearly validate the aberrant expression of KRT23 in CRC, we assessed the KRT23 protein levels by immunohistochemistry (IHC). The examination was carried out on the tissues derived from the same patients with CRC used in the RNA analysis. In accordance with the data obtained by qPCR, the IHC staining underlined the increased levels of KRT23 in the tumoral section compared to the corresponding peritumoral sample (<xref rid="pharmaceutics-16-01554-f004" ref-type="fig">Figure 4</xref>A). We also defined an immunoreactivity score from 0 to 3 based on positivity staining intensity (<italic toggle="yes">p</italic> &#x0003c; 0.0001, <xref rid="pharmaceutics-16-01554-f004" ref-type="fig">Figure 4</xref>B). The score reported in <xref rid="pharmaceutics-16-01554-f004" ref-type="fig">Figure 4</xref>B demonstrated once more the deregulation of KRT23 in patients with CRC.</p></sec><sec id="sec3dot3-pharmaceutics-16-01554"><title>3.3. miR-195-5p Modulates KRT23 Expression</title><p>In order to evaluate if miR-195-5p was able to modulate the KRT23 expression levels, we carried out transient transfection with synthetic compounds of miR-195-5p mimic at the concentrations of 30 nM and 50 nM in vitro. The gain of function of miR-195-5p in HCT116 and HT29 cell lines showed a significant reduction of <italic toggle="yes">KRT23</italic> at mRNA levels at both mimic concentrations (<italic toggle="yes">p</italic> &#x0003c; 0.001; <xref rid="pharmaceutics-16-01554-f005" ref-type="fig">Figure 5</xref>A).</p><p>In the same way, enhancing the miR-195-5p intracellular level, we examined whether miR-195-5p influenced the KRT23 protein expression. Even in this case, the miR-195-5p transfection at 30 nM and 50 nM was also able to markedly decrease the KRT23 protein expression level in transfected cells compared with mock control. (<italic toggle="yes">p</italic> &#x0003c; 0.001; <xref rid="pharmaceutics-16-01554-f005" ref-type="fig">Figure 5</xref>B).</p><p>In the reverse experiment, to additionally confirm the involvement of miR-195-5p in the regulation of KRT23 expression, we transiently transfected the CRC cell lines with molecules of miR-195-5p inhibitor. The decrease in intracellular levels of miR-195-5p in HCT116 and HT29 leads to a significant increase in KRT23 at mRNA levels (<italic toggle="yes">p</italic> &#x0003c; 0.01; <xref rid="pharmaceutics-16-01554-f006" ref-type="fig">Figure 6</xref>A). Interestingly, the inhibition of miR-195-p was able to upregulate the KRT23 protein expression levels (<italic toggle="yes">p</italic> &#x0003c; 0.01; <xref rid="pharmaceutics-16-01554-f006" ref-type="fig">Figure 6</xref>B). Altogether, these data confirm that miR-195-5p is responsible for the regulation of KRT23 expression levels.</p></sec><sec id="sec3dot4-pharmaceutics-16-01554"><title>3.4. miR-195-5p Affects Attachment and Detachment of CRC Cell Lines</title><p>In order to evaluate the potential clinical properties of miR-195-5p in the CRC suppression, we studied the influence of the miR-195-5p increment in attachment and detachment assays. The raise of miR-195-5p in HT29 and HCT116 induced a strong inhibition of the attachment/detachment ability in transfected conditions (ANOVA <italic toggle="yes">p</italic> &#x0003c; 0.0001; ANOVA <italic toggle="yes">p</italic> &#x0003c; 0.001; <xref rid="pharmaceutics-16-01554-f007" ref-type="fig">Figure 7</xref>).</p><p>In addition, we have assessed the migration and invasion ability of HCT116 and HT29 cells. According to cell attachment/detachment results, the transwell assay confirmed that the miR-195-5p gain markedly suppresses the migration and invasion rate of CRC cells, suggesting the positive effects of miR-195-5p in enhancing the assembly and function of cell adhesion (<xref rid="app1-pharmaceutics-16-01554" ref-type="app">Figure S1</xref>).</p></sec><sec id="sec3dot5-pharmaceutics-16-01554"><title>3.5. miR-195-5p Prevents the Colony Formation</title><p>To further define the contribution of miR-195-5p in CRC progression, we investigated its effect on CRC cell line clone formation ability. We overexpressed miR-195-5p in HT29 and HCT116, highlighting its function in suppressing the clonogenic potential of CRC cells. The induced expression of mature miR-195-5p at 30 nM and 50 nM concentrations resulted in a significant repression of the cell proliferation compared to untransfected conditions, suggesting the protective role of miR-195-5p in CRC (ANOVA <italic toggle="yes">p</italic> &#x0003c; 0.0001; <xref rid="pharmaceutics-16-01554-f008" ref-type="fig">Figure 8</xref>).</p></sec><sec id="sec3dot6-pharmaceutics-16-01554"><title>3.6. miR-195-5p Induces Apoptosis</title><p>To further evaluate the functional effects of miR-195-5p, we overexpressed miR-195-5p molecules in HCT116 and HT29 cell lines and examined their effect on cellular apoptosis. After transfection, we observed significant differences in the percentage of live cells and total apoptotic cells between transfected cells and mock controls in all cell lines (<italic toggle="yes">p</italic> &#x0003c; 0.05, <xref rid="app1-pharmaceutics-16-01554" ref-type="app">Figure S2A,B</xref>). Specifically, we found that raising miR-195-5p intracellular levels at 30 nM and 50 nM concentrations increased the proportions of total apoptotic cells that include early and late apoptotic cells (<xref rid="app1-pharmaceutics-16-01554" ref-type="app">Figure S2C,D</xref>).</p></sec><sec id="sec3dot7-pharmaceutics-16-01554"><title>3.7. In Vivo Determination of KRT23 Expression</title><p>In our recent study, we have elucidated the effectiveness of miR-195-5p, assessing a CRC mouse model induced by administration of azoxymethane (AOM)/dextran sodium sulfate (DSS) [<xref rid="B24-pharmaceutics-16-01554" ref-type="bibr">24</xref>]. In brief, we analyzed two groups of male C57BL/6 mice divided into a control group (vehicle, n = 14) and a treated group (miR-195-5p mimic, n = 14). In each animal, cycles of AOM and DSS were administered, followed by a cycle of 15 days of water. Until sacrifice, miR-195-5p mimic and vehicle were intraperitoneally injected twice a week.</p><p>Furthermore, to characterize the molecular mechanisms controlled by miR-195-5p in AOM/DSS mice models, we examined the <italic toggle="yes">KRT23</italic> expression in colon segments of mice obtained in our previous in vivo experiments [<xref rid="B24-pharmaceutics-16-01554" ref-type="bibr">24</xref>]. <italic toggle="yes">Krt23</italic> levels were found to be clearly reduced in medial as well as in distal colons of mice handled with intraperitoneal administration of miR-195-5p (<italic toggle="yes">p</italic> &#x0003c; 0.001; <xref rid="pharmaceutics-16-01554-f009" ref-type="fig">Figure 9</xref>).</p><p>Moreover, we also investigated the expression of KRT23 protein in the same colon tissue used for mRNA analysis. KRT23 protein levels were strongly decreased in the medial and distal colons of mice after miR-195-5p mimic administration (<xref rid="pharmaceutics-16-01554-f010" ref-type="fig">Figure 10</xref>). All these findings enhanced the suggestion of KRT23 and miR-195-5p as effective good candidate targets for CRC therapy.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-16-01554"><title>4. Discussion</title><p>The cell adhesion mechanisms involved in the connections to the internal cytoskeleton determine the tissue&#x02019;s architecture and function. The cytoskeleton impacts the cells pivotal functions through dynamic changes that provide structural support and organization, ensuring cell shape change and movement, guaranteeing mechanical resistance to stress, and integrating external stimuli [<xref rid="B25-pharmaceutics-16-01554" ref-type="bibr">25</xref>].</p><p>Keratins are epithelial-specific intermediate filament proteins that are generally classified as structural proteins, although in the last years several studies have recognized their active involvement in many cellular mechanisms, like protein synthesis, motility, cell growth, and signaling [<xref rid="B26-pharmaceutics-16-01554" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-16-01554" ref-type="bibr">27</xref>]. Keratins members have widely been exploited/employed for diagnostic purposes, but in the last few years, have been emerging as prognostic markers that are able to directly affect either epithelial tumorigenesis or treatment responsiveness [<xref rid="B28-pharmaceutics-16-01554" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-16-01554" ref-type="bibr">29</xref>].</p><p>The study concerning the multifactorial properties of keratins could facilitate the establishment of new therapeutic targets that allow earlier cancer diagnosis and more efficiency in cancer therapies [<xref rid="B30-pharmaceutics-16-01554" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-16-01554" ref-type="bibr">31</xref>]. In this context, KRT23 is a recently identified type I keratin component that guarantees the cell&#x02019;s structural integrity and is crucial for several cellular functions, such as apoptosis [<xref rid="B32-pharmaceutics-16-01554" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-16-01554" ref-type="bibr">33</xref>]. Since epithelial cells have a specific and variable signature of cytokeratin during development and differentiation that is only partially affected by malignant transformation, KRT23 was identified as a specific circulating marker of HCC [<xref rid="B34-pharmaceutics-16-01554" ref-type="bibr">34</xref>]. Other evidence has reported the KRT23-related mechanism of tumorigenesis in many types of tumors. In gastric cancer, KRT23 knockout inhibited the proliferation and arrested cell cycle progression through a reduced phosphorylation of ERK1/2 and p38 [<xref rid="B33-pharmaceutics-16-01554" ref-type="bibr">33</xref>]. Kim and colleagues demonstrated that the induction of KRT23 mediated by MYC transcriptional potentiation promotes HCC growth [<xref rid="B9-pharmaceutics-16-01554" ref-type="bibr">9</xref>]. Similarly, KRT23 overexpression facilitates the migration of ovarian tumor cells through EMT-regulating TGF-&#x003b2;/Smad signaling [<xref rid="B10-pharmaceutics-16-01554" ref-type="bibr">10</xref>]. In CRC, the downregulation of KRT23 affected the expression of genes involved in DNA damage response, affecting the proliferation of CRC cells and their responsiveness to radiation [<xref rid="B35-pharmaceutics-16-01554" ref-type="bibr">35</xref>]. In addition, overexpression of KRT23 induced the telomerase reverse transcriptase activity, promoting CRC cell migration [<xref rid="B36-pharmaceutics-16-01554" ref-type="bibr">36</xref>].</p><p>Taken together, these studies argued the tumorigenic properties of KRT23 but its molecular mechanisms and potential regulators in CRC are still not clearly clarified and require in-depth exploration.</p><p>miRNAs are an emerging class of non-coding RNAs that regulate human gene expression and could function as modulators in multiple pathological and biological progressions, such as cancer cell differentiation, proliferation, and apoptosis [<xref rid="B37-pharmaceutics-16-01554" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-16-01554" ref-type="bibr">38</xref>]. Growing evidence reported miRNAs as clinical, diagnostic, and prognostic biomarkers, as well as treatment approaches highlighting their properties as either oncogenes or tumor suppressors by directly targeting mRNAs and participating in the mechanism of tumor occurrence and development [<xref rid="B39-pharmaceutics-16-01554" ref-type="bibr">39</xref>]. In oral cancer cells, miR-485-5p suppresses keratin 17 (KRT17), which in turn represses the integrin &#x003b2;4/&#x003b1;6/FAK/Src/ERK/&#x003b2;-catenin pathway, impacting cancer progression and resistance to cisplatin and carboplatin [<xref rid="B40-pharmaceutics-16-01554" ref-type="bibr">40</xref>]. Moreover, a recent study assessed that the overexpression of miR-642 decreases the proliferation and migration of gastric tumor cells affecting the KRT19 expression [<xref rid="B41-pharmaceutics-16-01554" ref-type="bibr">41</xref>]. However, to date, investigations of miRNA involvement in CRC by regulating keratin members are still lacking.</p><p>Recently, we have demonstrated the miR-195-5p deregulation in patients with CRC and its critical potential role as a tumor suppressor [<xref rid="B24-pharmaceutics-16-01554" ref-type="bibr">24</xref>]. Indeed, we have documented that the in vitro gain of function of miR-195-5p strongly repressed colon cancer cell proliferation, viability, migration, and invasion [<xref rid="B23-pharmaceutics-16-01554" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-16-01554" ref-type="bibr">24</xref>], regulating desmosome junction. In addition, the miR-195-5p in vivo administration markedly decreased the number of malignant formations in the entire colon of AOM/DSS-treated mice as well as affected tumor growth [<xref rid="B24-pharmaceutics-16-01554" ref-type="bibr">24</xref>]. In this concern, we have further characterized a new miR-195-5p/PNN interaction involved in CRC development that affected the desmosome complex. In detail, we proved the miR-195-5p abilities reverse the overexpression of PNN in both in vitro and in vivo models. Moreover, PNN modulation by miR-195-5p indirectly increased the levels of KRT8 and KRT19, reinforcing the strength of adhesive junctions.</p><p>In this study, for the first time, we demonstrate a miR-195-5p/KRT23 axis. Starting from a bioinformatic analysis, we have determined that KRT23, a gene that encodes for a type I keratin protein, was a putative target of miR-195-5p. Consequently, we have examined the KRT23 expression in CRC using public cancer OMICS data from an online repository. Interestingly, the evaluation of KRT23 levels in tissue specimens collected in our institute of patients with CRC confirmed the KRT23 overexpression in the tumoral section compared to normal mucosa.</p><p>We have also proved that miR-195-5p increases in CRC cell lines manages the mRNA and protein expression of KRT23. On the other hand, we have also demonstrated that the inhibition of miR-195-5p in colonic cells increased the KRT23 expression, confirming the role of miR-195-5p on KRT23 regulation. Furthermore, with the aim of defining the potential effectiveness of miR-195-5p increase, we evaluated the cell attachment and detachment ability as well as cell clonogenic potential after miR-195-5p mimic transfection. Notably, after raising the intracellular level of miR-195-5p, we found that the cellular attach/detach potential, the migration/invasion abilities, and the relative proliferation rate were significantly suppressed. In vitro, miR-195-p impacted also on apoptosis process confirming its positive properties. Finally, we demonstrated that intraperitoneal delivery of miR-195-5p mimic lowered colonic KRT23 expression in the CRC mice model.</p><p>Our findings further highlighted the potential application of miR-195-5p, elucidating a novel regulatory mechanism of keratin intermediate filaments in CRC. However, future research will need to be conducted to clarify the molecular mechanisms related to KRT23 in CRC progression.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-16-01554"><title>5. Conclusions</title><p>In conclusion, our results support the potential clinical properties of miR-195-5p by targeting the KRT23 expression. We have proved that the recently discovered KRT23 was markedly overexpressed in tumoral tissues of patients with CRC and that miR-195-5p can reverse the KRT23 dysregulation in both CRC cell lines and AOM/DSS-treated mice. These results enhance the clinical significance of miR-195-5p in CRC.</p></sec><sec id="sec6-pharmaceutics-16-01554"><title>6. Patents</title><p>In Italy, a patent entitled &#x0201c;MiRNA or combination of miRNAs for therapy&#x0201d; was issued on 4 June 2024 to the Ente Ospedaliero Specializzato in Gastroenterologia &#x0201c;Saverio de Bellis&#x0201d;.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Mary V.C. Pragnell, B.A. for her language revision of the manuscript and Giusy Bianco for technical assistance.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-16-01554"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics16121554/s1">https://www.mdpi.com/article/10.3390/pharmaceutics16121554/s1</uri>, Figure S1. Migration and invasion transwell assay in HCT116 and HT29 cell lines after miR-195-5p transfection. Figure S2. Apoptotic profile of HCT116 and HT29 after transfection. File S1: Raw Data of All Western Blot Experiments.</p><supplementary-material id="pharmaceutics-16-01554-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-16-01554-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, E.P. and G.S.; data curation E.P., V.S. and G.S.; formal analysis, E.P., V.S., R.A. and G.S; Funding acquisition, G.G. and G.S.; Investigation, E.P., V.S., N.L., R.A. and G.S.; Methodology, E.P., V.S., N.L. and G.S.; project administration, G.S.; resources, G.S.; software, E.P. and G.S.; supervision, G.G. and G.S.; validation, E.P., V.S. and G.S; visualization, E.P., V.S., N.L., R.A. and G.S.; writing&#x02014;original draft, E.P.; writing&#x02014;review and editing, G.G. and G.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was carried out according to the principles of the Declaration of Helsinki and was approved by the local Institutional Ethics Review Boards (Istituto Tumori Giovanni Paolo II, Bari, Italy). Written informed consent was obtained from all study participants.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are within the article, <xref rid="app1-pharmaceutics-16-01554" ref-type="app">Supplementary Materials, and Supplementary File S1</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-16-01554"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hohmann</surname><given-names>T.</given-names></name>
<name><surname>Dehghani</surname><given-names>F.</given-names></name>
</person-group><article-title>The cytoskeleton&#x02014;A complex interacting meshwork</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>362</elocation-id><pub-id pub-id-type="doi">10.3390/cells8040362</pub-id><pub-id pub-id-type="pmid">31003495</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-16-01554"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bezanilla</surname><given-names>M.</given-names></name>
<name><surname>Gladfelter</surname><given-names>A.S.</given-names></name>
<name><surname>Kovar</surname><given-names>D.R.</given-names></name>
<name><surname>Lee</surname><given-names>W.-L.</given-names></name>
</person-group><article-title>Cytoskeletal dynamics: A view from the membrane</article-title><source>J. Cell Biol.</source><year>2015</year><volume>209</volume><fpage>329</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1083/jcb.201502062</pub-id><pub-id pub-id-type="pmid">25963816</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-16-01554"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fletcher</surname><given-names>D.A.</given-names></name>
<name><surname>Mullins</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Cell mechanics and the cytoskeleton</article-title><source>Nature</source><year>2010</year><volume>463</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nature08908</pub-id><pub-id pub-id-type="pmid">20110992</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-16-01554"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramaekers</surname><given-names>F.C.</given-names></name>
<name><surname>Bosman</surname><given-names>F.T.</given-names></name>
</person-group><article-title>The cytoskeleton and disease</article-title><source>J. Pathol.</source><year>2004</year><volume>204</volume><fpage>351</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1002/path.1665</pub-id><pub-id pub-id-type="pmid">15495261</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-16-01554"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Windoffer</surname><given-names>R.</given-names></name>
<name><surname>Beil</surname><given-names>M.</given-names></name>
<name><surname>Magin</surname><given-names>T.M.</given-names></name>
<name><surname>Leube</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Cytoskeleton in motion: The dynamics of keratin intermediate filaments in epithelia</article-title><source>J. Cell Biol.</source><year>2011</year><volume>194</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1083/jcb.201008095</pub-id><pub-id pub-id-type="pmid">21893596</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-16-01554"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loschke</surname><given-names>F.</given-names></name>
<name><surname>Seltmann</surname><given-names>K.</given-names></name>
<name><surname>Bouameur</surname><given-names>J.-E.</given-names></name>
<name><surname>Magin</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Regulation of keratin network organization</article-title><source>Curr. Opin. Cell Biol.</source><year>2015</year><volume>32</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2014.12.006</pub-id><pub-id pub-id-type="pmid">25594948</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-16-01554"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karantza</surname><given-names>V.</given-names></name>
</person-group><article-title>Keratins in health and cancer: More than mere epithelial cell markers</article-title><source>Oncogene</source><year>2011</year><volume>30</volume><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.456</pub-id><pub-id pub-id-type="pmid">20890307</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-16-01554"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toivola</surname><given-names>D.M.</given-names></name>
<name><surname>Boor</surname><given-names>P.</given-names></name>
<name><surname>Alam</surname><given-names>C.</given-names></name>
<name><surname>Strnad</surname><given-names>P.</given-names></name>
</person-group><article-title>Keratins in health and disease</article-title><source>Curr. Opin. Cell Biol.</source><year>2015</year><volume>32</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2014.12.008</pub-id><pub-id pub-id-type="pmid">25599598</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-16-01554"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Brocker</surname><given-names>C.N.</given-names></name>
<name><surname>Takahashi</surname><given-names>S.</given-names></name>
<name><surname>Yagai</surname><given-names>T.</given-names></name>
<name><surname>Kim</surname><given-names>T.</given-names></name>
<name><surname>Xie</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Qu</surname><given-names>A.</given-names></name>
<name><surname>Gonzalez</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Keratin 23 Is a Peroxisome Proliferator-Activated Receptor Alpha&#x02013;Dependent, MYC-Amplified Oncogene That Promotes Hepatocyte Proliferation</article-title><source>Hepatology</source><year>2019</year><volume>70</volume><fpage>154</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1002/hep.30530</pub-id><pub-id pub-id-type="pmid">30697791</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-16-01554"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Yue</surname><given-names>W.</given-names></name>
</person-group><article-title>The overexpression of keratin 23 promotes migration of ovarian cancer via epithelial-mesenchymal transition</article-title><source>Biomed. Res. Int.</source><year>2020</year><volume>2020</volume><elocation-id>8218735</elocation-id><pub-id pub-id-type="doi">10.1155/2020/8218735</pub-id><pub-id pub-id-type="pmid">33204716</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-16-01554"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liffers</surname><given-names>S.-T.</given-names></name>
<name><surname>Maghnouj</surname><given-names>A.</given-names></name>
<name><surname>Munding</surname><given-names>J.B.</given-names></name>
<name><surname>Jackstadt</surname><given-names>R.</given-names></name>
<name><surname>Herbrand</surname><given-names>U.</given-names></name>
<name><surname>Schulenborg</surname><given-names>T.</given-names></name>
<name><surname>Marcus</surname><given-names>K.</given-names></name>
<name><surname>Klein-Scory</surname><given-names>S.</given-names></name>
<name><surname>Schmiegel</surname><given-names>W.</given-names></name>
<name><surname>Schwarte-Waldhoff</surname><given-names>I.</given-names></name>
</person-group><article-title>Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3&#x003b5;</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><elocation-id>137</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-11-137</pub-id><pub-id pub-id-type="pmid">21492476</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-16-01554"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dexheimer</surname><given-names>P.J.</given-names></name>
<name><surname>Cochella</surname><given-names>L.</given-names></name>
</person-group><article-title>MicroRNAs: From mechanism to organism</article-title><source>Front. Cell Dev. Biol.</source><year>2020</year><volume>8</volume><elocation-id>409</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.00409</pub-id><pub-id pub-id-type="pmid">32582699</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-16-01554"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bueno</surname><given-names>M.J.</given-names></name>
<name><surname>de Castro</surname><given-names>I.P.</given-names></name>
<name><surname>Malumbres</surname><given-names>M.</given-names></name>
</person-group><article-title>Control of cell proliferation pathways by microRNAs</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><fpage>3143</fpage><lpage>3148</lpage><pub-id pub-id-type="doi">10.4161/cc.7.20.6833</pub-id><pub-id pub-id-type="pmid">18843198</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-16-01554"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piccinno</surname><given-names>E.</given-names></name>
<name><surname>Scalavino</surname><given-names>V.</given-names></name>
<name><surname>Labarile</surname><given-names>N.</given-names></name>
<name><surname>De Marinis</surname><given-names>L.</given-names></name>
<name><surname>Armentano</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
<name><surname>Serino</surname><given-names>G.</given-names></name>
</person-group><article-title>Identification of a Novel miR-195-5p/PNN Axis in Colorectal Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>5980</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25115980</pub-id><pub-id pub-id-type="pmid">38892168</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-16-01554"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scalavino</surname><given-names>V.</given-names></name>
<name><surname>Piccinno</surname><given-names>E.</given-names></name>
<name><surname>Lacalamita</surname><given-names>A.</given-names></name>
<name><surname>Tafaro</surname><given-names>A.</given-names></name>
<name><surname>Armentano</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
<name><surname>Serino</surname><given-names>G.</given-names></name>
</person-group><article-title>miR-195-5p regulates tight junctions expression via Claudin-2 downregulation in ulcerative colitis</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>919</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10040919</pub-id><pub-id pub-id-type="pmid">35453669</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-16-01554"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scalavino</surname><given-names>V.</given-names></name>
<name><surname>Piccinno</surname><given-names>E.</given-names></name>
<name><surname>Valentini</surname><given-names>A.M.</given-names></name>
<name><surname>Mastronardi</surname><given-names>M.</given-names></name>
<name><surname>Armentano</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
<name><surname>Serino</surname><given-names>G.</given-names></name>
</person-group><article-title>A novel mechanism of immunoproteasome regulation via miR-369-3p in intestinal inflammatory response</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>13771</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232213771</pub-id><pub-id pub-id-type="pmid">36430249</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-16-01554"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scalavino</surname><given-names>V.</given-names></name>
<name><surname>Piccinno</surname><given-names>E.</given-names></name>
<name><surname>Valentini</surname><given-names>A.M.</given-names></name>
<name><surname>Schena</surname><given-names>N.</given-names></name>
<name><surname>Armentano</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
<name><surname>Serino</surname><given-names>G.</given-names></name>
</person-group><article-title>miR-369-3p modulates intestinal inflammatory response via BRCC3/NLRP3 inflammasome axis</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>2184</elocation-id><pub-id pub-id-type="doi">10.3390/cells12172184</pub-id><pub-id pub-id-type="pmid">37681916</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-16-01554"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hussen</surname><given-names>B.M.</given-names></name>
<name><surname>Hidayat</surname><given-names>H.J.</given-names></name>
<name><surname>Salihi</surname><given-names>A.</given-names></name>
<name><surname>Sabir</surname><given-names>D.K.</given-names></name>
<name><surname>Taheri</surname><given-names>M.</given-names></name>
<name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></name>
</person-group><article-title>MicroRNA: A signature for cancer progression</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>138</volume><elocation-id>111528</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111528</pub-id><pub-id pub-id-type="pmid">33770669</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-16-01554"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ichimi</surname><given-names>T.</given-names></name>
<name><surname>Enokida</surname><given-names>H.</given-names></name>
<name><surname>Okuno</surname><given-names>Y.</given-names></name>
<name><surname>Kunimoto</surname><given-names>R.</given-names></name>
<name><surname>Chiyomaru</surname><given-names>T.</given-names></name>
<name><surname>Kawamoto</surname><given-names>K.</given-names></name>
<name><surname>Kawahara</surname><given-names>K.</given-names></name>
<name><surname>Toki</surname><given-names>K.</given-names></name>
<name><surname>Kawakami</surname><given-names>K.</given-names></name>
<name><surname>Nishiyama</surname><given-names>K.</given-names></name>
</person-group><article-title>Identification of novel microRNA targets based on microRNA signatures in bladder cancer</article-title><source>Int. J. Cancer</source><year>2009</year><volume>125</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1002/ijc.24390</pub-id><pub-id pub-id-type="pmid">19378336</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-16-01554"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.-C.</given-names></name>
<name><surname>Jang</surname><given-names>T.-H.</given-names></name>
<name><surname>Tung</surname><given-names>S.-L.</given-names></name>
<name><surname>Yen</surname><given-names>T.-C.</given-names></name>
<name><surname>Chan</surname><given-names>S.-H.</given-names></name>
<name><surname>Wang</surname><given-names>L.-H.</given-names></name>
</person-group><article-title>A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing &#x003b2;5-integrin/c-met signaling pathway</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2019</year><volume>38</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1091-5</pub-id><pub-id pub-id-type="pmid">30782177</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-16-01554"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Kang</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>W98</fpage><lpage>W102</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><pub-id pub-id-type="pmid">28407145</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-16-01554"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sticht</surname><given-names>C.</given-names></name>
<name><surname>De La Torre</surname><given-names>C.</given-names></name>
<name><surname>Parveen</surname><given-names>A.</given-names></name>
<name><surname>Gretz</surname><given-names>N.</given-names></name>
</person-group><article-title>miRWalk: An online resource for prediction of microRNA binding sites</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0206239</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0206239</pub-id><pub-id pub-id-type="pmid">30335862</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-16-01554"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piccinno</surname><given-names>E.</given-names></name>
<name><surname>Scalavino</surname><given-names>V.</given-names></name>
<name><surname>Armentano</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
<name><surname>Serino</surname><given-names>G.</given-names></name>
</person-group><article-title>miR-195-5p as Regulator of &#x003b3;-Catenin and Desmosome Junctions in Colorectal Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>17084</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242317084</pub-id><pub-id pub-id-type="pmid">38069408</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-16-01554"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piccinno</surname><given-names>E.</given-names></name>
<name><surname>Scalavino</surname><given-names>V.</given-names></name>
<name><surname>Labarile</surname><given-names>N.</given-names></name>
<name><surname>Bianco</surname><given-names>G.</given-names></name>
<name><surname>Savino</surname><given-names>M.T.</given-names></name>
<name><surname>Armentano</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
<name><surname>Serino</surname><given-names>G.</given-names></name>
</person-group><article-title>Downregulation of &#x003b3;-Catenin by miR-195-5p Inhibits Colon Cancer Progression, Regulating Desmosome Function</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>25</volume><elocation-id>494</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25010494</pub-id><pub-id pub-id-type="pmid">38203664</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-16-01554"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Peng</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Cui</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
</person-group><article-title>Roles of the cytoskeleton in human diseases</article-title><source>Mol. Biol. Rep.</source><year>2023</year><volume>50</volume><fpage>2847</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.1007/s11033-022-08025-5</pub-id><pub-id pub-id-type="pmid">36609753</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-16-01554"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Wong</surname><given-names>P.</given-names></name>
<name><surname>Coulombe</surname><given-names>P.A.</given-names></name>
</person-group><article-title>A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth</article-title><source>Nature</source><year>2006</year><volume>441</volume><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/nature04659</pub-id><pub-id pub-id-type="pmid">16710422</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-16-01554"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moujaber</surname><given-names>O.</given-names></name>
<name><surname>Stochaj</surname><given-names>U.</given-names></name>
</person-group><article-title>The cytoskeleton as regulator of cell signaling pathways</article-title><source>Trends Biochem. Sci.</source><year>2020</year><volume>45</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2019.11.003</pub-id><pub-id pub-id-type="pmid">31812462</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-16-01554"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barak</surname><given-names>V.</given-names></name>
<name><surname>Goike</surname><given-names>H.</given-names></name>
<name><surname>Panaretakis</surname><given-names>K.W.</given-names></name>
<name><surname>Einarsson</surname><given-names>R.</given-names></name>
</person-group><article-title>Clinical utility of cytokeratins as tumor markers</article-title><source>Clin. Biochem.</source><year>2004</year><volume>37</volume><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2004.05.009</pub-id><pub-id pub-id-type="pmid">15234234</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-16-01554"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linder</surname><given-names>S.</given-names></name>
<name><surname>Olofsson</surname><given-names>M.H.</given-names></name>
<name><surname>Herrmann</surname><given-names>R.</given-names></name>
<name><surname>Ulukaya</surname><given-names>E.</given-names></name>
</person-group><article-title>Utilization of cytokeratin-based biomarkers for pharmacodynamic studies</article-title><source>Expert Rev. Mol. Diagn.</source><year>2010</year><volume>10</volume><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1586/erm.10.14</pub-id><pub-id pub-id-type="pmid">20370591</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-16-01554"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawant</surname><given-names>S.S.</given-names></name>
<name><surname>Zingde</surname><given-names>S.M.</given-names></name>
<name><surname>Vaidya</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Cytokeratin fragments in the serum: Their utility for the management of oral cancer</article-title><source>Oral Oncol.</source><year>2008</year><volume>44</volume><fpage>722</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2007.10.008</pub-id><pub-id pub-id-type="pmid">18203649</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-16-01554"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holdenrieder</surname><given-names>S.</given-names></name>
<name><surname>Stieber</surname><given-names>P.</given-names></name>
<name><surname>Liska</surname><given-names>V.</given-names></name>
<name><surname>Treska</surname><given-names>V.</given-names></name>
<name><surname>Topolcan</surname><given-names>O.</given-names></name>
<name><surname>Dreslerova</surname><given-names>J.</given-names></name>
<name><surname>Matejka</surname><given-names>V.</given-names></name>
<name><surname>Finek</surname><given-names>J.</given-names></name>
<name><surname>Holubec</surname><given-names>L.</given-names></name>
</person-group><article-title>Cytokeratin serum biomarkers in patients with colorectal cancer</article-title><source>Anticancer Res.</source><year>2012</year><volume>32</volume><fpage>1971</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">22593474</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-16-01554"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Birkenkamp-Demtroder</surname><given-names>K.</given-names></name>
<name><surname>Mansilla</surname><given-names>F.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>F.B.</given-names></name>
<name><surname>Kruh&#x000f8;ffer</surname><given-names>M.</given-names></name>
<name><surname>Cabez&#x000f3;n</surname><given-names>T.</given-names></name>
<name><surname>Christensen</surname><given-names>L.L.</given-names></name>
<name><surname>Aaltonen</surname><given-names>L.A.</given-names></name>
<name><surname>Verspaget</surname><given-names>H.W.</given-names></name>
<name><surname>&#x000d8;rntoft</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro</article-title><source>Mol. Oncol.</source><year>2007</year><volume>1</volume><fpage>181</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2007.05.005</pub-id><pub-id pub-id-type="pmid">19383294</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-16-01554"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Luo</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Feng</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>R.</given-names></name>
</person-group><article-title>Loss of keratin 23 enhances growth inhibitory effect of melatonin in gastric cancer</article-title><source>Mol. Med. Rep.</source><year>2024</year><volume>29</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.3892/mmr.2023.13145</pub-id><pub-id pub-id-type="pmid">38099343</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-16-01554"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Nie</surname><given-names>Y.</given-names></name>
<name><surname>Dai</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma</article-title><source>Cancer Lett.</source><year>2009</year><volume>281</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.02.037</pub-id><pub-id pub-id-type="pmid">19304375</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-16-01554"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Birkenkamp-Demtr&#x000f6;der</surname><given-names>K.</given-names></name>
<name><surname>Hahn</surname><given-names>S.A.</given-names></name>
<name><surname>Mansilla</surname><given-names>F.</given-names></name>
<name><surname>Thorsen</surname><given-names>K.</given-names></name>
<name><surname>Maghnouj</surname><given-names>A.</given-names></name>
<name><surname>Christensen</surname><given-names>R.</given-names></name>
<name><surname>&#x000d8;ster</surname><given-names>B.</given-names></name>
<name><surname>&#x000d8;rntoft</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e73593</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0073593</pub-id><pub-id pub-id-type="pmid">24039993</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-16-01554"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>N.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Zou</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>W.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Tai</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
</person-group><article-title>Keratin 23 promotes telomerase reverse transcriptase expression and human colorectal cancer growth</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2961</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.339</pub-id><pub-id pub-id-type="pmid">28749462</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-16-01554"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hill</surname><given-names>M.</given-names></name>
<name><surname>Tran</surname><given-names>N.</given-names></name>
</person-group><article-title>miRNA interplay: Mechanisms and consequences in cancer</article-title><source>Dis. Model. Mech.</source><year>2021</year><volume>14</volume><fpage>dmm047662</fpage><pub-id pub-id-type="doi">10.1242/dmm.047662</pub-id><pub-id pub-id-type="pmid">33973623</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-16-01554"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartel</surname><given-names>D.P.</given-names></name>
</person-group><article-title>MicroRNAs: Target recognition and regulatory functions</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id><pub-id pub-id-type="pmid">19167326</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-16-01554"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartel</surname><given-names>D.P.</given-names></name>
</person-group><article-title>MicroRNAs: Genomics, biogenesis, mechanism, and function</article-title><source>Cell</source><year>2004</year><volume>116</volume><fpage>281</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id><pub-id pub-id-type="pmid">14744438</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-16-01554"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jang</surname><given-names>T.-H.</given-names></name>
<name><surname>Huang</surname><given-names>W.-C.</given-names></name>
<name><surname>Tung</surname><given-names>S.-L.</given-names></name>
<name><surname>Lin</surname><given-names>S.-C.</given-names></name>
<name><surname>Chen</surname><given-names>P.-M.</given-names></name>
<name><surname>Cho</surname><given-names>C.-Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Yen</surname><given-names>T.-C.</given-names></name>
<name><surname>Lo</surname><given-names>G.-H.</given-names></name>
<name><surname>Chuang</surname><given-names>S.-E.</given-names></name>
</person-group><article-title>MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/&#x003b2;-catenin pathway</article-title><source>J. Biomed. Sci.</source><year>2022</year><volume>29</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-022-00824-z</pub-id><pub-id pub-id-type="pmid">35706019</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-16-01554"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mi</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Mu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Overexpression miR-642 Inhibits Cell Migration and Proliferation by Regulation of KRT19 and Clinical Prognosis Value in Gastric Cancer</article-title><source>J. Int. Soc. Sports Nutr.</source><year>2023</year><volume>2766</volume><fpage>2276</fpage><pub-id pub-id-type="doi">10.37871/jbres1713</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-16-01554-f001"><label>Figure 1</label><caption><p>miR-195-5p targets <italic toggle="yes">KRT23</italic> binding two specific sequences in CDS mRNA. miRwalk algorithm was used for the analysis founding that miR-195-5p links <italic toggle="yes">KRT23</italic> CDS in two different sites.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g001" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f002"><label>Figure 2</label><caption><p><italic toggle="yes">KRT23</italic> expression in CRC. GEPIA tool investigation highlighted a statistically significant deregulation of <italic toggle="yes">KRT23</italic> between tumor and healthy control status. * <italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g002" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f003"><label>Figure 3</label><caption><p><italic toggle="yes">KRT23</italic> expression in patients with CRC (n = 30). (<bold>A</bold>) The RNA was extracted to perform qPCR analysis starting from FFPE tissue blocks that include tumor and adjacent normal colon. Our results demonstrated the crucial increase in expression of <italic toggle="yes">KRT23</italic> in CRC tissue. ** <italic toggle="yes">p</italic> &#x0003c; 0.001. (<bold>B</bold>) Pearson correlation in CRC tissues demonstrated a negative correlation between miR-195-5p and <italic toggle="yes">KRT23</italic> expression, indicating that miR-195-5p may be involved in the regulation of <italic toggle="yes">KRT23</italic>. r = &#x02212;0.249, <italic toggle="yes">p</italic> &#x0003c; 0.05. Each point represents a sample.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g003" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f004"><label>Figure 4</label><caption><p>KRT23 protein expression at IHC in FFPE tissues of patients with CRC. (<bold>A</bold>) Representative images acquired at 4&#x000d7; original magnification showing a strong stain in CRC tissue compared to adjacent normal mucosa. (<bold>B</bold>) The immunoreactivity score quantified the signal intensity that corresponds to the KRT23 expression in colonic epithelium *** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g004" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f005"><label>Figure 5</label><caption><p>KRT23 expression in mimic transfected cell lines. (<bold>A</bold>) KRT23 gene expression was assessed in HCT116 (<bold>left</bold>) and HT29 (<bold>right</bold>) transfected cells. The raise of miR-195-5p at 30 nM and 50 nM concentrations by transient transfection led to a valuable reduction of KRT23 in both cell lines. Expression data were normalized on the Gapdh housekeeping gene. Graphs are representative of four independent experiments (mean &#x000b1; SEM). ** <italic toggle="yes">p</italic> &#x0003c; 0.001; *** <italic toggle="yes">p</italic> &#x0003c; 0.0001. (<bold>B</bold>) KRT23 protein expression in mimic transfected cells. The increase in intracellular levels of miR-195-5p induced an effective decrease in KRT23 levels in both cell lines. KRT23 values were obtained by dividing the normalized transfected sample values by the normalized mock-control sample values. Normalization was performed on the values of &#x003b2;-tubulin housekeeping protein. <xref rid="app1-pharmaceutics-16-01554" ref-type="app">Supplementary File S1</xref> contained the raw data for all Western blot experiments. ** <italic toggle="yes">p</italic> &#x0003c; 0.001; *** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g005" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f006"><label>Figure 6</label><caption><p>KRT23 expression after miR-195-5p inhibitor transfection. In HCT116 and HT29 cells, KRT23 mRNA (<bold>A</bold>) and protein expression (<bold>B</bold>) levels were significantly increased after transfection compared to mock control confirming the KRT23 regulation by miR-195-5p. mRNA expression data were normalized on the GAPDH housekeeping gene. KRT23 protein values were obtained by dividing the normalized transfected sample values by the normalized mock-control sample values. Data were normalized on the values of &#x003b2;-tubulin housekeeping protein. <xref rid="app1-pharmaceutics-16-01554" ref-type="app">Supplementary File S1</xref> contained the raw data for all Western blot experiments. ** <italic toggle="yes">p</italic> &#x0003c; 0.001; *** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g006" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f007"><label>Figure 7</label><caption><p>miR-195-5p mimic inhibits cell attachment and detachment. (<bold>A</bold>,<bold>B</bold>) Attachment assay employed on HCT116 (<bold>left</bold>) and HT29 (<bold>right</bold>) after mimic transfection. In transfected conditions, the relative attachment of cells was found to be deeply reduced compared to mock control. The values were obtained by dividing the values of the normalized transfected sample with the normalized mock-control sample and derived at least from four independent experiments. ANOVA <italic toggle="yes">p</italic> &#x0003c; 0.0001 (<bold>C</bold>,<bold>D</bold>) Detachment rate of HCT116 and HT29 following mimic transient transfection. The intracellular increase level of miR-195-5p affected the detachment capacity of transfected cells. The data were presented as a percentage of the detached cells to total cells and are presented as the mean&#x02009; &#x000b1; &#x02009;SEM of at least four independent experiments. ANOVA <italic toggle="yes">p</italic> &#x0003c; 0.001 * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.001, *** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g007" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f008"><label>Figure 8</label><caption><p>miR-195-5p mimic effectiveness on the formation of HCT-116 cell (<bold>A</bold>,<bold>B</bold>) and HT29 cell (<bold>C</bold>,<bold>D</bold>) colonies. Transient transfection with molecules of miR-195-5p markedly decreased the cell proliferative rates. After transfection, cell clonogenic potential was significantly declined. For each cell line, the representative images of the colony formation assay and the relative proliferation rate are shown. Magnification 4&#x000d7;. The results are presented as the mean of at least four independent experiments &#x000b1; SEM. ANOVA <italic toggle="yes">p</italic> &#x0003c; 0.0001; ** <italic toggle="yes">p</italic> &#x0003c; 0.001; *** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g008" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f009"><label>Figure 9</label><caption><p>Impact of miR-195-5p mimic administration on <italic toggle="yes">Krt23</italic> expression in CRC mice model (n = 14 mice/group). <italic toggle="yes">Krt23</italic> expression in both medial (<bold>A</bold>) and distal colon segments (<bold>B</bold>) was significantly decreased in the miR-195-5p-treated group as compared with vehicle mice. Expression data were normalized on housekeeping gene <italic toggle="yes">Gapdh</italic> and are shown as mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x0003c; 0.01, ** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g009" position="float"/></fig><fig position="float" id="pharmaceutics-16-01554-f010"><label>Figure 10</label><caption><p>miR-195-5p in vivo effect on KRT23 protein expression in AOM/DSS mice (n = 14 mice/group). According to mRNA data, KRT23 protein expression in the medial and distal colons was strongly reduced in miR-195-5p-treated mice compared to the vehicle group. Each single-channel image derived from DAPI and KRT23 signals is merged. Original magnification: 20&#x000d7;.</p></caption><graphic xlink:href="pharmaceutics-16-01554-g010" position="float"/></fig><table-wrap position="float" id="pharmaceutics-16-01554-t001"><object-id pub-id-type="pii">pharmaceutics-16-01554-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and clinical characteristics of patients with CRC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients with CRC (n = 30)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Sex</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Female (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (44.4)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Male (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">17 (56.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Age at diagnosis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mean &#x000b1; SD</td><td align="left" valign="middle" rowspan="1" colspan="1">69.4 &#x000b1; 12.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">TNM stage</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;II (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (40)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;III (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">17 (56.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IV (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Nodal status</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Positive (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">18 (60)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Negative (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (40)</td></tr></tbody></table></table-wrap></floats-group></article>